← Eichor
Condition: Myelodysplastic Syndrome Acute Myeloid Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myelodysplastic Syndrome Acute Myeloid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 2 · 1 location(s) · University of Manitoba · NCT06599762Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT06484062Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07019155CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT05143996Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Phase 1 · 1 location(s) · University of Virginia · NCT07270978Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 · 1 location(s) · Eric Stephen Winer, MD · NCT05703542IS-free Treg HaploHCT
Phase 1 · 1 location(s) · Dana-Farber Cancer Institute · NCT04678401Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Phase 1 · 2 location(s) · Remedy Plan, Inc. · NCT07107126Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297576Caris Chromoseq Data Collection
Phase N/A · 1 location(s) · Caris Science, Inc. · NCT07680868Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119The Patient Cohort of the National Center for Precision Medicine in Leukemia
Phase N/A · 3 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05326919Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Home Blood Transfusions
NA · 1 location(s) · Thomas Jefferson University · NCT07121140
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.